Logo image of BPTH

BIO-PATH HOLDINGS INC (BPTH) Stock Fundamental Analysis

NASDAQ:BPTH - Nasdaq - US09057N4097 - Common Stock

0.8423  +0.02 (+2.72%)

After market: 0.8121 -0.03 (-3.59%)

Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to BPTH. BPTH was compared to 572 industry peers in the Biotechnology industry. BPTH may be in some trouble as it scores bad on both profitability and health. BPTH is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BPTH has reported negative net income.
In the past year BPTH has reported a negative cash flow from operations.
In the past 5 years BPTH always reported negative net income.
BPTH had a negative operating cash flow in each of the past 5 years.
BPTH Yearly Net Income VS EBIT VS OCF VS FCFBPTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M

1.2 Ratios

With a Return On Assets value of -354.57%, BPTH is not doing good in the industry: 96.28% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -354.57%
ROE N/A
ROIC N/A
ROA(3y)-208.48%
ROA(5y)-145.89%
ROE(3y)-1261.55%
ROE(5y)-779.53%
ROIC(3y)N/A
ROIC(5y)N/A
BPTH Yearly ROA, ROE, ROICBPTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K

1.3 Margins

BPTH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BPTH Yearly Profit, Operating, Gross MarginsBPTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20K -40K -60K

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, BPTH has more shares outstanding
The number of shares outstanding for BPTH has been increased compared to 5 years ago.
BPTH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BPTH Yearly Shares OutstandingBPTH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K
BPTH Yearly Total Debt VS Total AssetsBPTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M

2.2 Solvency

Based on the Altman-Z score of -67.58, we must say that BPTH is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -67.58, BPTH is not doing good in the industry: 95.75% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -67.58
ROIC/WACCN/A
WACCN/A
BPTH Yearly LT Debt VS Equity VS FCFBPTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M

2.3 Liquidity

BPTH has a Current Ratio of 0.86. This is a bad value and indicates that BPTH is not financially healthy enough and could expect problems in meeting its short term obligations.
BPTH has a Current ratio of 0.86. This is amonst the worse of the industry: BPTH underperforms 89.91% of its industry peers.
A Quick Ratio of 0.86 indicates that BPTH may have some problems paying its short term obligations.
BPTH has a Quick ratio of 0.86. This is amonst the worse of the industry: BPTH underperforms 88.85% of its industry peers.
Industry RankSector Rank
Current Ratio 0.86
Quick Ratio 0.86
BPTH Yearly Current Assets VS Current LiabilitesBPTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 66.03% over the past year.
EPS 1Y (TTM)66.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.06%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

BPTH is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.40% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y91.32%
EPS Next 2Y39.91%
EPS Next 3Y25.14%
EPS Next 5Y15.4%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BPTH Yearly Revenue VS EstimatesBPTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 20M 40M 60M 80M 100M
BPTH Yearly EPS VS EstimatesBPTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -100 -200 -300

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BPTH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BPTH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BPTH Price Earnings VS Forward Price EarningsBPTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BPTH Per share dataBPTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -2 -4 -6 -8 -10

4.3 Compensation for Growth

BPTH's earnings are expected to grow with 25.14% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.91%
EPS Next 3Y25.14%

More info and screens

0

5. Dividend

5.1 Amount

BPTH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIO-PATH HOLDINGS INC

NASDAQ:BPTH (1/21/2025, 8:00:00 PM)

After market: 0.8121 -0.03 (-3.59%)

0.8423

+0.02 (+2.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)N/A N/A
Inst Owners5.59%
Inst Owner Change0%
Ins Owners0.07%
Ins Owner Change0%
Market Cap3.63M
Analysts82.86
Price Target12.24 (1353.16%)
Short Float %5.8%
Short Ratio0.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)29.44%
Min EPS beat(2)26.15%
Max EPS beat(2)32.72%
EPS beat(4)2
Avg EPS beat(4)6.37%
Min EPS beat(4)-28%
Max EPS beat(4)32.72%
EPS beat(8)4
Avg EPS beat(8)-2.97%
EPS beat(12)5
Avg EPS beat(12)-7.88%
EPS beat(16)9
Avg EPS beat(16)-0.13%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-40%
EPS NQ rev (1m)0%
EPS NQ rev (3m)92.37%
EPS NY rev (1m)0%
EPS NY rev (3m)48.87%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-13.79
EYN/A
EPS(NY)-1.58
Fwd EYN/A
FCF(TTM)-2.21
FCFYN/A
OCF(TTM)-2.21
OCFYN/A
SpS0
BVpS-0.17
TBVpS-0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -354.57%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-208.48%
ROA(5y)-145.89%
ROE(3y)-1261.55%
ROE(5y)-779.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.86
Quick Ratio 0.86
Altman-Z -67.58
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.06%
EPS Next Y91.32%
EPS Next 2Y39.91%
EPS Next 3Y25.14%
EPS Next 5Y15.4%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y26.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y26.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.32%
OCF growth 3YN/A
OCF growth 5YN/A